Imperial College London


Faculty of Natural SciencesDepartment of Chemistry




+44 (0)20 7594 5806d.klug




Molecular Sciences Research HubWhite City Campus





David Klug joined the Department of Chemistry in October 1998, having from October 1995 held a joint position in the Departments of Biochemistry and Chemistry.  From October 1990 to September 1995 he was a Royal Society University Research Fellow jointly in Biochemistry and Chemistry.  He graduated in Physics at University College London in 1984, and obtained his Ph.D. at The Royal Institution in 1987.

David is co-founder of the Institute of Chemical Biology  ( ), which co-ordinates teaching and research activities in Chemical Biology. He also chaired the Single Cell Proteomics Project, a £5 million multidisciplinary collaboration of eight research teams developing and applying novel platform technologies to high throughput and single cell analysis and the Proxomics Project, platform technologies for the analysis of oxidative damage to proteins.

Current research interests are focused on the development and deployment of two platform technologies. 1) EVV 2DIR spectroscopy for the analysis of drug-target binding contacts and geometry. 2) Single molecule-sensitive affinity assays for the analysis of single and rare human primary cells in a variety of contexts.

David is currently Associate Dean for Enterprise and works with Imperial College start-ups and strategic partners. He assists with bringing Imperial College inventions to the wider world for socio-economic benefit.

David is also Chief Scientific Officer of Panacea Diagnostics, a company dedicated to the development of a universal platform for monitoring health and the early detection of disease.






Chrysostomou S, Roy R, Prischi F, et al., 2022, Re: Repurposed Floxacins Targeting RSK4 Prevent Chemoresistance and Metastasis in Lung and Bladder Cancer, Journal of Urology, Vol:207, ISSN:0022-5347, Pages:919-920

Klug D, Osman S, Bendtsen C, et al., 2021, Evaluation of FOXO1 target engagement using a single-cell microfluidic platform, Analytical Chemistry, Vol:93, ISSN:0003-2700, Pages:14659-14666

Pardo O, Chrysostomou S, Roy R, et al., 2021, Repurposed floxacins targeting RSK4 prevent chemoresistance and metastasis in lung and bladder cancer, Science Translational Medicine, Vol:13, ISSN:1946-6234


Ho V, Baker JR, Willison KR, et al., 2022, Novel Single Cell Analysis of microRNA Levels in Response to Oxidative Stress and in COPD Using Microfluidic Technology, International Conference of the American-Thoracic-Society, AMER THORACIC SOC, ISSN:1073-449X

Ho V, Willison K, Baker J, et al., 2021, Microfluidic single cell analysis of microRNA levels in small airway epithelial cells and fibroblasts from COPD patients, EUROPEAN RESPIRATORY SOC JOURNALS LTD, ISSN:0903-1936

More Publications